US FDA Rebukes Another Sponsor For Touting Investigational Product Based On Subgroup Efficacy

CytoDyn’s COVID-19 candidate leronlimab joins BrainStorm’s ALS therapy in being taken to task as FDA has become more willing to publicly counter investigational drug data announcements it considers to be misleading.